VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic β cell carcinogenesis

Cancer Cell

Volumn 1, Issue 2, 2002, Pages 193-202

  Inoue, Masahiro ^a,c   Hager, Jeffrey H ^a   Ferrara, Napoleone ^b   Gerber, Hans Peter ^b   Hanahan, Douglas ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b GENENTECH INC   (United States)

^c OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

VASCULOTROPIN A; ENDOTHELIAL CELL GROWTH FACTOR; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; LYMPHOKINE; RALBP1 PROTEIN, MOUSE; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ARTICLE; CANCER GRADING; CELL DISRUPTION; CONTROLLED STUDY; KNOCKOUT MOUSE; LIGAND BINDING; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; ONCOGENE; PANCREAS ISLET CELL CARCINOMA; PRECANCER; PRIORITY JOURNAL; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; ANIMAL; ANTIBODY SPECIFICITY; CELL DIVISION; GENE DELETION; GENE EXPRESSION PROFILING; GENETICS; HUMAN; METABOLISM; PANCREAS ISLET; PANCREAS TUMOR; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSGENIC MOUSE; VASCULARIZATION;

ANIMALS; CELL DIVISION; ENDOTHELIAL GROWTH FACTORS; GENE DELETION; GENE EXPRESSION PROFILING; GTPASE-ACTIVATING PROTEINS; HUMANS; ISLETS OF LANGERHANS; LYMPHOKINES; MICE; MICE, TRANSGENIC; NEOVASCULARIZATION, PATHOLOGIC; ORGAN SPECIFICITY; PANCREATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0036491615     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1535-6108(02)00031-4     Document Type: Article

References (32)

1. Bergers, G., Javaherian, K., Lo, K.M., Folkman, J., and Hanahan, D. (1999). Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 284, 808-812.
2. Bergers, G., Brekken, R., McMahon, G., Vu, T.H., Itoh, T., Tamaki, K., Tanzawa, K., Thorpe, P., Itohara, S., Werb, Z., and Hanahan, D. (2000). Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat. Cell Biol. 2, 737-744.
3. Carmeliet, P., Ferreira, V., Breier, G., Pollefeyt, S., Kieckens, L., Gertsenstein, M., Fahrig, M., Vandenhoeck, A., Harpal, K., Eberhardt, C., et al. (1996). Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380, 435-439.
4. Christofori, G., and Luef, S. (1997). Novel forms of acidic fibroblast growthfactor-1 are constitutively exported by b tumor cell lines independent from conventional secretion and apoptosis. Angiogenesis 1, 55-70.
5. Christofori, G., Naik, P., and Hanahan, D. (1995). Vascular endothelial growth factor and its receptors, flt-1 and flk-1, are expressed in normal pancreatic islets and throughout islet cell tumorigenesis. Mol. Endocrinol. 9, 1760-1770.
6. Compagni, A., Wilgenbus, P., Impagnatiello, M.A., Cotten, M., and Christofori, G. (2000). Fibroblast growth factors are required for efficient tumor angiogenesis. Cancer Res. 60, 7163-7169.
7. Ferrara, N. (1999). Molecular and biological properties of vascular endothelial growth factor. J. Mol. Med. 77, 527-543.
8. Ferrara, N., Carver-Moore, K., Chen, H., Dowd, M., Lu, L., O'Shea, K.S., Powell-Braxton, L., Hillan, K.J., and Moore, M.W. (1996). Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380, 439-442.
9. Folkman, J., Watson, K., Ingber, D., and Hanahan, D. (1989). Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339, 58-61.
10. Gannon, M., Shiota, C., Postic, C., Wright, C.V., and Magnuson, M. (2000). Analysis of the Cre-mediated recombination driven by rat insulin promoter in embryonic and adult mouse pancreas. Genesis 26, 139-142.
11. Gannon, G., Mandriota, S.J., Cui, L., Baetens, D., Pepper, M.S., and Christofori, G. (2002). Overexpression of vascular endothelial growth factor-A165 enhances tumor angiogenesis but not metastasis during beta-cell carcinogenesis. Cancer Res. 62, 603-608.
12. Gerber, H.P., Hillan, K.J., Ryan, A.M., Kowalski, J., Keller, G.A., Rangell, L., Wright, B.D., Radtke, F., Aguet, M., and Ferrara, N. (1999). VEGF is required for growth and survival in neonatal mice. Development 126, 1149-1159.
13. Gerber, H.P., Kowalski, J., Sherman, D., Eberhard, D.A., and Ferrara, N. (2000). Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor. Cancer Res. 60, 6253-6258.
14. Hanahan, D. (1985). Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature 315, 115-122.
15. Hanahan, D., and Folkman, J. (1996). Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86, 353-364.
16. Hanahan, D., and Weinberg, R.A. (2000). The hallmarks of cancer. Cell 100, 57-70.
17. Hart, A.W., Baeza, N., Apelqvist, A., and Edlund, H. (2000). Attenuation of FGF signalling in mouse beta-cells leads to diabetes. Nature 408, 864-868.
18. Holash, J., Maisonpierre, P.C., Compton, D., Boland, P., Alexander, C.R., Zagzag, D., Yancopoulos, G.D., and Wiegand, S.J. (1999a). Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 284, 1994-1998.
19. Holash, J., Wiegand, S.J., and Yancopoulos, G.D. (1999b). New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF. Oncogene 18, 5356-5362.
20. Itakura, J., Ishiwata, T., Shen, B., Kommann, M., and Korc, M. (2000). Concomitant over-expression of vascular endothelial growth factor and its receptors in pancreatic cancer. Int. J. Cancer 85, 27-34.
21. Kulkarni, R.N., Bruning, J.C., Winnay, J.N., Postic, C., Magnuson, M.A., and Kahn, C.R. (1999). Tissue-specific knockout of the insulin receptor in pancreatic beta cells creates an insulin secretory defect similar to that in type 2 diabetes. Cell 96, 329-339.
22. Kunkel, P., Ulbricht, U., Bohlen, P., Brockmann, M.A., Fillbrandt, R., Stavrou, D., Westphal, M., and Lamszus, K. (2001). Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res. 61, 6624-6628.
23. Lammert, E., Cleaver, O., and Melton, D. (2001). Induction of pancreatic differentiation by signals from blood vessels. Science 294, 564-567.
24. Luo, J., Guo, P., Matsuda, K., Truong, N., Lee, A., Chun, C., Cheng, S.Y., and Korc, M. (2001). Pancreatic cancer cell-derived vascular endothelial growth factor is biologically active in vitro and enhances tumorigenicity in vivo. Int. J. Cancer 92, 361-369.
25. Mandriota, S.J., Jussila, L., Jeltsch, M., Compagni, A., Baetens, D., Prevo, R., Banerji, S., Huarte, J., Montesano, R., Jackson, D.G., et al. (2001). Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J. 20, 672-682.
26. Parangi, S., Dietrich, W., Christofori, G., Lander, E.S., and Hanahan, D. (1995). Tumor suppressor loci on mouse chromosomes 9 and 16 are lost at distinct stages of tumorigenesis in a transgenic model of islet cell carcinoma. Cancer Res. 55, 6071-6076.
27. Pezzella, F., Pastorino, U., Tagliabue, E., Andreola, S., Sozzi, G., Gasparini, G., Menard, S., Gatter, K.C., Harris, A.L., Fox, S., et al. (1997). Non-small-cell lung carcinoma tumor growth without morphological evidence of neoangiogenesis. Am. J. Pathol. 151, 1417-1423.
28. Postic, C., Shiota, M., Niswender, K.D., Jetton, T.L., Chen, Y., Moates, J.M., Shelton, K.D., Lindner, J., Cherrington, A.D., and Magnuson, M.A. (1999). Dual roles for glucokinase in glucose homeostasis as determined by liver and pancreatic beta cell-specific gene knock-outs using Cre recombinase. J. Biol. Chem. 274, 305-315.
29. Rubenstein, J.L., Kim, J., Ozawa, T., Zhang, M., Westphal, M., Deen, D.F., and Shuman, M.A. (2000). Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2, 306-314.
30. Shibuya, M., Ito, N., and Claesson-Welsh, L. (1999). Structure and function of vascular endothelial growth factor receptor-1 and -2. Curr. Top. Microbiol. Immunol. 237, 59-83.
31. Vajkoczy, P., Menger, M.D., Vollmar, B., Schilling, L., Schmiedek, P., Hirth, K.P., Ullrich, A., and Fong, T.A. (1999). Inhibition of tumor growth, angiogenesis, and microcirculation by the novel Flk-1 inhibitor SU5416 as assessed by intravital multi- fluorescence videomicroscopy. Neoplasia 1, 31-41.
32. Van Dyke, T., and Jacks, T. (2002). Cancer modeling in the modern era. Progress and challenges. Cell 108, 135-144.